Rpg Life Sciences Limited · NSE:RPGLIFE
Rpg Life Sciences — RPG Annual Investor Conference 2023
12 slides from Rpg Life Sciences's conference presentation, Jun 14, 2023
Slide 1: Regulation 30 disclosure cover letter to stock exchanges
RPG LIFE SCIENCES LIMITED L Regd. Off.: RPG House 463, Dr. Annie Besant Road Wor1i, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax:+91-22-24970127 Email: info@rpglifesciences.com RPO LIFE SCIENCES www.rpglifesciences.com CIN: L24232MH2007PLG169354 June 14, 2023 The Manager BSE Limited List
Slide 2: Annual Investor Conference 2023
hello happiness Annual Investor Conference 2023 RPG Life Sciences June 15, 2023
Slide 3: Disclaimer
Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures,
Slide 4: RPG Life Sciences: An Integrated Pharmaceutical Company
RPG Life Sciences: An Integrated Pharmaceutical Company RPG Life Sciences is an integrated research based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. Domestic Formulations (DF) Leader in Immunosuppr
Slide 5: FY 2022-23: A Milestone Year
FY 2022-23: A Milestone Year First time ever Consistently outperforming the IPM market– 20.0%* vs 7.9%**growth 500 Cr+ Revenues Naprosyn: First 50 Cr+ Brand for the company 100 Cr+ EBITDA New products and therapies contributed 28% 100 Cr+ Cash in Hand 1000 Cr+ Share price crossed INR 1,000 first tim
Slide 6: Margins: A Trajectory of y-o-y expansion continues
Margins: A Trajectory of y-o-y expansion continues EBITDA% 21.0% 20.3% PBT% 18.2% 17.9% 16.6% ` 15.9% PAT% 13.8% 11.1% 11.1% 13.2% 10.4% 9.8% 9.3% 11.7% 8.7% 8.1% 10.3% 6.0% 6.2% 5.9% 4.7% 7.7% 4.2% 4.6% 4.2% 3.9% 3.9% 0.9% 0.4% 0.4% 3.3% 0.5% 0.2% FY 12 FY 13 FY 14 FY 15 FY 16 FY 17 FY 18 FY 19 FY
Slide 7: Key Financial Metrics: A Trajectory of Strong y-o-y Growth
Key Financial Metrices : A Trajectory of Strong y-o-y Growth 1' Revenues 1' EPS 40.9 512.8 31.1 440.2 er: u 375.6 389.1 z 24.2 er: z 330.2 C 17.5 IIII C 6.5 FY19 FY20 FY21 FY22 FY23 ■ FY19 FY20 FY21 FY22 FY23 1' Cash Flows 1' Dividend 115.2 12.0 ~ "' ..c 9.6 70.3 V) ,._ u (I) 7.2 I er: a. ~ 40.3 er:
Slide 8: Key Ratios (ROCE, ROE): A Trajectory of y-o-y uptrend
Key Ratios (ROCE, ROE) : A Trajectory of y-o-y uptrend ROCE % ROE % 22.0% 29.1% 20.1% 27.9% 18.5% 23.6% 24.3% 16.4% 11.0% 6.7% I FY19 FY20 FY21 FY22 FY23 I FY19 FY20 FY21 FY22 FY23 Company continues to remain Debt-free 7 ~» R?G I £ R?Q U,'ESC,ENCES
Slide 9: Journey of RPG Life Sciences
Journey of RPG Life Sciences 1 2 Process Excellence Product Portfolio, People, Business Processes Fundamentals Fixing Sales Hygiene, People, Organization 3 Sustainable Profitable Growth Revenues, Volumes, Margins 4 Benchmark 5 Performance Profitability, Leverage, Liquidity Ratios Scale-up 8
Slide 10: ESG Progress Update FY23
ESG Progress Update FY23 Environment Goals Social Goals .. Governance Goals Carbon Emission Diversity & Inclusion Data Integrity 10% reduction in FY23 50% increase in gender Digitalization across Plants diversity in FY23 Energy Consumption Product Responsibility Cybersecurity [E 8% reduction in FY23
Slide 11: The Journey Ahead: Benchmark Performance to Scale-up
The Journey Ahead: Benchmark Performance to Scale-up 7 Pillars identified • Modern, Cost-efficient; cGMP Compliant; • EU/PICS/TGA etc approved • Higher Capacity ~2X • Org structure review & role/skill-gaps identification • Focused New Product Grid across 3 State-of-art segments • Talent Development
Slide 12: hello happiness
•• V hello happiness
RPG Life Sciences — RPG Annual Investor Conference 2023 on 6ix